E-Posters-10054

10054_Henderson

Pdf Summary

This study retrospectively looked at the treatment practices within specialty clinics for patients utilizing third-line therapies for overactive bladder (OAB). The objective was to assess the usage and follow-up rates of advanced therapies for OAB. The study analyzed ambulatory billing data from 7 Cleveland area specialty providers from January 2012 to January 2016. Female OAB patients undergoing third-line therapies were compared to those who did not proceed to third-line therapies. <br /><br />The results showed that few patients with OAB proceed to third-line therapies in specialty clinics, and follow-up after these therapies is poor. Patients utilizing third-line therapies were generally older, suffering from neurodegenerative diseases and lung disease. Patients utilizing Interstim® and Botox® were more likely to report significant improvement in OAB symptoms compared to PTNS. <br /><br />The study also found that patients proceeding to third-line therapies were seen more times compared to those not proceeding to third-line therapy. The time to third-line therapies ranged from 140 to 355 days. <br /><br />In conclusion, this study provides insights into the utilization of third-line therapies for OAB in specialty hospital systems. It highlights the demographic characteristics of patients utilizing these therapies and the differences in improvement rates between different therapy options. The study also emphasizes the need for improved follow-up after third-line therapies.

Keywords

specialty clinics

third-line therapies

overactive bladder

usage rates

follow-up rates

ambulatory billing data

Cleveland area

female patients

neurodegenerative diseases

lung disease